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Abstract
Breast cancer incidence and mortality are higher in women with a high socioeconomic status (SES). The potential to prevent death
from breast cancer is therefore greater in the high SES group. This does, however, require that the effectiveness of screening in the
high SES group is equal to or greater than the effectiveness in the low SES group. The aim of this study is to assess the relative
effectiveness of mammographic screening on breast cancer mortality by SES.
In Nijmegen, the Netherlands, women are invited to participate in biennial mammographic screening since 1975. Postal code is
collected at each round and is used to calculate the SES of each woman based on the SES indicator of the Netherlands Institute for
Social Research. The Dutch average was used to classify the SES score of each woman as either high or low. We designed a case-
control study to investigate the effect of mammographic screening in women aged 50 to 75, 40 to 75, and 50 to 69 years, and
calculated the odds ratios (ORs) and 95% conﬁdence intervals (CIs).
Among the women invited to the mammographic screening program in Nijmegen, 10% had a high SES. In women aged 50 to
75 years, the breast cancer death rate was 38% lower in screened women than in unscreened women. The ORs for women with high
SES (OR 0.82, 95% CI 0.31–2.19) and low SES did not differ signiﬁcantly (OR 0.61, 95% CI 0.47–0.78).
Mammographic screening reduces breast cancer mortality, but we did not observe a signiﬁcant difference in the relative
effectiveness of screening by SES. If the effectiveness of mammographic screening is indeed not dependent on SES status, the
absolute number of breast cancer deaths prevented bymammographic screeningwill be greater in the high SES than lowSES group,
because women with a high SES have a greater risk of breast cancer death.
Abbreviations: CI= conﬁdence interval, EDM-BV= Evers Direct Marketing Besloten Vennootschap, ER= estrogen receptor, IQR
= interquartile range, OR = odds ratio, PR = progesterone receptor, SCP = socioeconomic score of the Netherlands Institute for
Social Research, SES = socioeconomic status.
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1. Introduction
Many European countries have implemented a population-based
mammographic screening program.[1] Virtually all programs
deﬁne the target population invited to screening by age alone.
Because mammographic screening beneﬁts some women and
harms others,[2,3] the question is arising whether mammographic
screening can be optimized, that is, obtaining a more favorable
beneﬁt–harm balance. A more favorable balance between the
beneﬁts and harms of screening may be achieved by more
targeted screening, that is, deﬁning a target population for
screening based on more risk factors in addition to age.
A potential risk factor for breast cancer that can be considered
in this respect is socioeconomic status (SES). SES is associated
with a range of risk factors for breast cancer, such as a mother’s
age at ﬁrst childbirth and alcohol consumption.[4–6] In addition,
previous research has shown that women with higher SES have a
higher breast cancer incidence and mortality than women with
low SES.[4,7,8] The absolute number of breast cancers prevented
by mammographic screening may, therefore, be higher in women
with high SES than in women with low SES. The prerequisite is
that the effectiveness of mammographic screening in women with
high SES is equal to or greater than the effectiveness of screening
in women with low SES.[9] Because high SES is associated with a
higher breast density,[10] which can mask tumors on mammo-
grams[11]; the relative effect of screening might actually be smaller
in women with high SES than low SES.
Only 1 study[9] investigated the relative effect of mammo-
graphic screening in younger women (aged 40–49 years) with
either high or low SES. In women aged 40 to 49 years, the relative
effect of mammographic screening on breast cancer mortality did
not differ signiﬁcantly between women with high and low SES.[9]
However, the effect of screening on breast cancer mortality in
womenwith either high or low SES remains unknown in the most
commonly targeted age groups.[1] Therefore, the aim of this study
is to investigate the relative effect of mammographic screening on
breast cancer mortality in women with either high or low SES
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(based on income, employment, and education) aged 50 to 75, 40
to 75, and 50 to 69 years.
2. Methods
2.1. Setting
The case-control study was conducted within the population
invited to the biennial mammographic screening program in
Nijmegen, the Netherlands. In 1975, at the initiation of the
program, women aged 35 years and over were invited for
screening. In 1989, at the start of the national screening program,
the targeted age range was limited to 50 to 69 years conforming
to national screening policy. In 1998, the national program also
started to invite women aged 70 to 75 years. Until 2014, the ﬁrst
screening examination consisted of 2 views (mediolateral oblique
and craniocaudal view), and the subsequent screening examina-
tions consisted of 1 view (lateral view in ﬁrst 3 rounds and
mediolateral view from the fourth round onwards). Additional
craniocaudal views during subsequent screening increased over
time. From 2014 onwards, 2 views became standard in
subsequent screening examinations (mediolateral oblique and
craniocaudal view). Mammograms are read independently by 2
radiologists who must reach consensus on recall. In 2007 to
2008, digital mammography was introduced.
The Nijmegen screening registry holds data on screening
attendance, age, and postal code per screening round. It also
collects information on vital status (date of death or migration)
and cause of death of women diagnosed with breast cancer who
are living in Nijmegen. Vital status is obtained from the
Municipal Personal Records Database (GBA), and cause of
death is assessed by a committee that is unaware of the screening
history. All women consented to the use of their anonymous data
for scientiﬁc research.
2.2. SES indicator
Socioeconomic status was based on the scores of the Netherlands
Institute for Social Research (SCP score).[12] This SCP score is
available for all 4-digit postal codes with more than 100
households and is provided every 4 years by the Netherlands
Institute for Social Research since 1995. The score is based on
mean household income, percentage of households with a low
income, percentage of inhabitants without a paid job, and
percentage of households with a low mean education. This
information is obtained via phone calls from the organization
Evers Direct Marketing Besloten Vennootschap (EDM-BV) to 1
person in each 6-digit postal code (usually 1 street) and
aggregated to 4-digit postal codes.
We made groups of high and low SES based on the SCP score
using the mean score of each 4-year period (0.26 for
1995–1998, 0.12 for 1999–2002, 0.21 for 2003–2006, and
0.17 for 2007–2010). The SES indicator in the period 1995 to
2002 was used to determine the SES in the period 1975 to 1994,
assuming that the SES did not change from high to low or vice
versa in this time period. Nijmegen had a lower mean SES score
than the Netherlands and covered about one-third of the total
range of the SCP scores.
2.3. Study design
We used a case-control study to evaluate the effect of
mammographic screening on breast cancer mortality in women
with a high and low SES (see Supplement 1 for STROBE
checklist, http://links.lww.com/MD/B166). Cases were deﬁned as
women who were aged 50 to 75, 40 to 75, or 50 to 69 years at
diagnosis, were invited to participate in the mammographic
screening program, were living in Nijmegen, and died from breast
cancer before January 1, 2013. For each case, 5 controls were
sampled according to the incidence density sampling procedure
using the syntax of Richardson.[13] Controls had to be of the same
age range as the cases, invited to participate in the screening
program at the time of diagnosis of the case, living in Nijmegen,
and alive at the time of death of the case.
Breast cancer screening is only effective in the period that
breast cancer is detectable by the screening test and not yet
symptomatic. Because the detectable preclinical period is
unknown at individual level, we set the time frame for invitation
at 4 years before the diagnosis of the case based on estimated lead
times for breast cancer.[14,15] In biennial screening, a 4-year
period covers 2 consecutive screening invitations: the invitation
before breast cancer diagnosis of the case (index invitation) and
the invitation preceding the index invitation (preindex invita-
tion). The age at index invitation and SES at index invitation were
used to determine the age and SES, respectively, of both the cases
and referents.
2.4. Statistical analyses
We used a chi-square test for independence to compare the
clinical characteristics of the cases with high and low SES.
Unconditional logistic regression was used to calculate the odds
ratio (OR) of the breast cancer mortality rate in women with high
and low SES accepting or declining the screening invitation.
Unconditional logistic regression results in an unbiased OR if the
proportion of women screened remains stable during the study
period.[16] In the Nijmegen screening program, the percentage of
attendance was relatively stable (Fig. 1).
We calculated ORs and their corresponding 95% conﬁdence
intervals (95% CIs) for women with high and low SES separately
and combined. TheORs were calculated for 3 age ranges, thereby
covering most of the targeted age ranges in Europe: 50 to 75 (the
Netherlands), 40 to 75 (Sweden), and 50 to 69 (Norway, Italy).[1]
All analyses were adjusted for age and executed in SAS version
9.2 (SAS Institute Inc., Cary, NC).
3. Results
3.1. Study population
In the period 1975 to 2012, 10% of the women invited for
screening had a high SES and 89% of the women had a low SES.
SES was unknown for 0.24% of the women aged 50 to 75 years.
The percentage of high SES increased over time: from 4% in 1975
to 20% in 2012. The attendance percentages were slightly higher
for women with high SES than for women with low SES (see
Fig. 1A–C). For women aged 50 to 75 years, the average
attendance was 67.4% for low SES and 73.0% for high SES. For
women aged 40 to 75 and 50 to 69 years, the average attendance
was 69.1% and 70.7% for low SES, and 73.1% and 72.3% for
high SES, respectively.
3.2. Case-control study
In the study period, 370 women aged 50 to 75, 451 women aged
40 to 75, and 313 women aged 50 to 69 years died from breast
Ripping et al. Medicine (2016) 95:31 Medicine
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cancer (cases). Table 1 presents the clinical characteristics of the
cases stratiﬁed by SES, which shows that the cases with high and
low SES do not differ statistically signiﬁcantly with respect to
mode of detection, age at diagnosis, lymph node status, tumor
size, breast density, estrogen receptor (ER), and progesterone
receptor (PR) status. The cases with high and low SES differed
only signiﬁcantly with respect to treatment, that is, type of
surgery and therapy after surgery (see Table 1). We randomly
sampled 5 controls per case, leading to 1850, 2255, and 1565
controls in the age groups 50 to 75, 40 to 75, and 50 to 69 years,
respectively. The median age at index invitation was 61
(interquartile range [IQR] 55–67) for the cases aged 50 to 75
years, and 59 (IQR 54–66) for the controls aged 50 to 75 years.
For women aged 40 to 75 and 50 to 69 years, the median age at
index invitation was 58 years (IQR 51–66) and 59 years (IQR
54–63) for cases, and 57 years (IQR 50–64) and 58 years (IQR
54–63) for controls, respectively.
Table 2 shows that screened women experience a lower breast
cancer mortality rate than unscreened women. The overall
mortality reduction by screening adjusted for age was 38% (OR
0.62, 95% CI 0.49–0.80) for women aged 50 to 75 years, 29%
(OR 0.71, 95% CI 0.57–0.89) for women aged 40 to 75 years,
and 38% (OR 0.62, 95% CI 0.48–0.82) for women aged 50 to
69 years. The effect of SES on the effectiveness of mammographic
screening was not signiﬁcant and differed with age group. The
effectiveness was higher for high SES than for low SES in women
aged 40 to 75 and 50 to 69 years, whereas the effectiveness
was lower for high SES than for low SES in women aged 50 to
75 years. For women aged 50 to 75 years, the age-adjusted
mortality reduction by screening was 39% (OR 0.61, 95% CI
0.47–0.78) for low SES and 18% (OR 0.82, 95% CI 0.31–2.19)
for women with high SES. For women aged 40 to 75 years, the
age-adjusted mortality reduction by screening was 28% (OR
0.72, 95% CI 0.57–0.91) for low SES and 43% (OR 0.56, 95%
CI 0.25–1.29) for high SES.
A range of 2 to 10 women, selected either as case or referent,
had a missing SES at the index round. The ORs changedmaximal
0.03 point when women with missing SES at the index round
were included in the analyses using the SES of another roundwith
known SES and closest to the index round.
4. Discussion
To the best of our knowledge, this is the ﬁrst study investigating
the relative effect of screening on breast cancer mortality in
women with high and low SES in the target age range of most
European screening programs. We showed that mammographic
screening reduces breast cancer mortality in women with high
and low SES, but that the relative effectiveness of screening does
not differ signiﬁcantly between women with high SES and low
SES in this study.
4.1. Effectiveness
So far, only 1 study investigated the effectiveness of mammo-
graphic screening for women with high and low SES aged 40 to
49 years.[9] This study showed, like the study reported here, no
statistically signiﬁcant difference in the relative effectiveness of
mammographic screening by SES. The absence of a difference in
the relative effect of mammographic screening by SESmay be real
or not found because of limitations of the current study.
A difference in the relative effect of mammographic screening
by SES may be expected because women with high and low SES
may differ in treatment,[17] mammography test characteristics,[18]
and/or breast cancer awareness.[19] Adequate treatment after the
detection of breast cancers by screening is essential for screening
to be effective.[20] Previous studies indicated that treatment
inequalities between women with low SES and high SES may
explain the lower survival from screen-detected breast cancer for
women with low SES.[17,21] In the current study, we found also a
signiﬁcant difference in type of surgery and therapy after surgery
between cases with high and low SES. Women with low SES had
more frequent no surgery (due to refusal of the patient, patient’s
age, or patient’s medication) or no treatment after surgery than
women with high SES. The main source of the treatment
inequalities is probably not SES itself, but rather the higher
presence of comorbid conditions in women with low SES.[22,23]
Based on the differences in treatment, it can be expected that the
relative effect of mammographic screening is smaller for women
with low SES than for women with high SES.
Figure 1. The screening attendance over time for women with a high and
low SES aged 50 to 75 (A), 40 to 75 (B), and 50 to 69 (C) years.
SES=socioeconomic status.
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However, there are more factors that can potentially inﬂuence
the effectiveness of mammographic screening by SES and that
have an opposite effect, that is, mammographic test character-
istics and breast cancer awareness.Mammographic screening test
characteristics, such as sensitivity, may be lower for women with
high SES. This is mainly because SES is positively associated with
breast density,[10] and high breast density can mask tumors on
mammograms.[11] SES itself is not likely to affect the screening
test characteristics in the Netherlands, because quality of
screening does not depend on SES and evaluating radiologists
are unaware of SES. Furthermore, the relative effect of
mammographic screening may be smaller for women with high
SES than for womenwith low SES, because womenwith high SES
have higher breast cancer awareness.[19] A high breast cancer
awareness is associated with cancer-related behavior such as
healthcare seeking.[19] As a consequence, women with high SES
who did not participate in the index or the preindex round may
still have been detected early, leading to a smaller effect of
screening in women with high than low SES. Because the effect
of treatment and breast cancer awareness are in an opposite
direction, if existing in our study population, they may cancel out
and result in an unobservable effect in this study.
4.2. Limitations and strengths
The absence of a difference in the relative effect of mammo-
graphic screening may also be the result of limitations of the
current study. In this study, SES was based on an area-based
measure, which does not capture individual as well as an
individual-level SES measure.[24] Furthermore, we extrapolated
the SES of the period 1995 to 1998 to the period 1975 to 1994.
These 2 limitations of the SES indicator used in this study may
have caused misclassiﬁcation of SES and attenuated the effect of
SES towards the null. Besides this, Nijmegen had in general a low
SES, especially in the early years, leading to a small number of
cases with high SES. As a consequence, the OR for women with
high SES had wide CIs. This problem can be overcome by using a
larger number of cases, that is, by linking national cancer and
screening registries. We would, however, like to point out that
Hellquist et al[9] also found no signiﬁcant difference in the
effectiveness of mammographic screening by SES, even though
this study had an individual measure and a high number of
women who died from breast cancer.
Our study also had strengths and limitations related to study
design, study population, and external validity. Major strengths
of our study were the use of a population-based approach,
histological ascertainment of breast cancer, and accurate
ascertainment of cause of death by a panel. We had a long
period of follow-up, which has both advantages and disadvan-
tages. The long follow-up of this study resulted from the nature of
our study, that is, prospective and population-based, which is a
strength. However, it should be recognized that during the
follow-up period, the screening program had changed, for
example, in the number of mammograms taken and in the
radiological equipment. Another limitation of our study is the
risk of self-selection bias, because we compared attenders with
nonattenders whomay have a different background risk of breast
cancer. Self-selection bias in the Netherlands is, however, is
small,[25] and we did not adjust for self-selection because it is
related to SES. Furthermore, our study population covered only
about one-third of the SES range in the Netherlands, thereby
excluding the most extreme SES groups. We cannot exclude the
possibility that the highest and lowest SES groups have a different
impact on the effectiveness of mammographic screening,
although this seems unlikely. Caution should also be taken in
generalizing the results of this study to other countries, because
SES is not an uniform concept[26] and depends on cultural
factors.[8] We did, however, use a combination of factors that are
often use to conceptualize SES, that is, education, income, and
Table 1
Clinical characteristics of cases aged 40 to 75 years at diagnosis.
N (%)
P∗High SES Low SES
Mode of detection 0.85
Screen-detected 11 (34%) 133 (31%)
Interval 8 (25%) 124 (30%)
Interval >24 mos 6 (19%) 91 (22%)
Nonparticipant 7 (22%) 71 (17%)
Age at diagnosis, y 0.98
40–49 5 (16%) 76 (18%)
50–59 12 (38%) 157 (37%)
60–69 11 (34%) 133 (32%)
70–75 4 (13%) 53 (13%)
Lymph node status 0.14
Positive 22 (69%) 225 (54%)
Negative 5 (16%) 135 (32%)
Unknown 5 (16%) 59 (14%)
Tumor size, mm 0.34
<10 2 (6%) 15 (4%)
10–14 0 (0%) 32 (8%)
15–19 3 (9%) 42 (10%)
20–29 5 (16%) 103 (25%)
>30 14 (44%) 139 (33%)
Diffuse 0 (0%) 6 (1%)
Unknown 8 (25%) 82 (20%)
Breast density 0.08
Nondense 11 (34%) 225 (54%)
Dense 14 (44%) 141 (34%)
Unknown 7 (22%) 53 (13%)
ER status 0.38
Positive 17 (53%) 235 (56%)
Weakly positive 0 (0%) 13 (3%)
Negative 11 (34%) 105 (25%)
Unknown 4 (13%) 66 (16%)
PR status 0.28
Positive 11 (34%) 178 (42%)
Weakly positive 1 (3%) 21 (5%)
Negative 16 (50%) 143 (34%)
Unknown 4 (13%) 77 (18%)
Surgery 0.02
Mastectomy 22 (69%) 286 (68%)
Breast-conserving surgery 3 (9%) 65 (16%)
Biopsy 2 (6%) 18 (4%)
Therapy-preceding surgery† 4 (3%) 10 (2%)
No surgery 0 (0%) 13 (3%)
Unknown 1 (3%) 27 (6%)
Therapy after surgery 0.004
No therapy 1 (3%) 27 (7%)
Chemotherapy 3 (9%) 21 (5%)
Radiotherapy 3 (9%) 73 (19%)
Hormone therapy 8 (25%) 71 (18%)
Else 1 (3%) 0 (0%)
Unknown 16 (50%) 192 (50%)
ER= estrogen receptor, PR=progesterone receptor, SES= socioeconomic status.
∗
Cases with missing data on the variable lymph node status, tumor size, breast density, ER status and/
or PR status, surgery, and therapy after surgery (i.e., unknown group) were excluded for the calculation
of the P value.
† Includes chemotherapy (8), radiotherapy (1), and hormone therapy (5).
Ripping et al. Medicine (2016) 95:31 Medicine
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employment, and this combination of factors may have the same
effect on the effectiveness of mammographic screening in
countries that are comparable with the Netherlands.
4.3. Usefulness of SES in personalized screening
Finally, we would like to discuss the potential usefulness of SES in
personalized screening. Factors relevant for personalized screening
should be able to differentiate women with a more favorable
beneﬁt–harms balance from women with a less favorable, or even
unfavorable, beneﬁt–harm balance. SES seems to have this
potential: assuming that the effectiveness of screening does not
vary by SES, it can be expected that the absolute number of breast
cancer deaths prevented by screening, that is, the beneﬁt, is higher
for women with a high SES. However, the harms of screening
(false-positives, false-negatives, and overdiagnosis) should not be
disproportionally higher forwomenwithhighSES than forwomen
with low SES.Wewould further like to point out that discussion is
needed to decide whether it is ethical to use SES as a factor for
personalized screening. It iswell-known thatwomenwith high SES
generally have lower all-causemortality andhigher life expectancy.
Thus, if a personalized screening program would result in a more
favorable beneﬁt–harmbalance forwomenwith high SES than low
SES, this would lead to further health inequality.
5. Conclusions
To conclude, mammographic screening reduces breast cancer
mortality in women targeted in most European mammographic
screening programs, that is, women aged 50 to 75, 40 to 75, and
50 to 69 years. We did not observe a difference in the relative
effect of mammographic screening on the breast cancer mortality
between women with high and low SES. If the absence of a
difference in the effectiveness of mammographic screening in
women with low and high SES is real, the absolute number of
breast cancers prevented will be higher for women with high SES
than for women with low SES.
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